{"id":18307,"date":"2024-02-09T09:37:43","date_gmt":"2024-02-09T09:37:43","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/"},"modified":"2024-02-09T13:05:07","modified_gmt":"2024-02-09T13:05:07","slug":"genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/","title":{"rendered":"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients"},"content":{"rendered":"<p id=\"tw-target-text\" class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><span class=\"Y2IQFc\" lang=\"en\"><strong>Genenta Science<\/strong> (NASDAQ: GNTA), a clinical-stage immuno-oncology (I\/O) company developing a cell-based platform that harnesses the power of <strong>hematopoietic stem cells<\/strong> to deliver durable, safe treatments for solid tumors, announced who successfully dosed the first of three patients in Cohort 8 (Temferon\u2122 at 4&#215;10^6\/kg), the final cohort of the variable-dose Phase 1 portion of the uMGMT Glioblastoma Multiforme Phase 1\/2 clinical trial newly diagnosed (TEM -GBM).<\/span><\/p>\n<p dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><strong>THE FIRST RESULTS:\u00a0<\/strong><\/p>\n<p class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\">Preliminary data indicate:<\/p>\n<ul>\n<li><strong>No dose-limiting toxicities<\/strong> related to Temferon have been detected in any of <strong>22 treated patients<\/strong>.<\/li>\n<li>Temferon-derived differentiated cells were evident within the peripheral blood 14 days after infusion and were still detectable at <strong>more than 24 months<\/strong>.<\/li>\n<\/ul>\n<p>As of December 2023, preliminary data in uMGMT patients, the most aggressive form of GBM, show a <strong>2-year Overall Survival (OS) of 25%<\/strong>; the historically reported data observed in uMGMT and methilated patients undergoing current standard of care is approximately 14% to 18%, respectively.<\/p>\n<p class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><span class=\"Y2IQFc\" lang=\"it\"><strong>Dr. Luigi Naldini<\/strong>, co-founder of Genenta and Director at the San Raffaele &#8211; Telethon Institute for Gene Therapy, stated:<\/span><\/p>\n<blockquote>\n<p class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><span class=\"Y2IQFc\" lang=\"it\">&#8220;Several techniques, including RNA single-cell analysis, suggest that <strong>Temferon can reprogram the Tumor Microenvironment (TME) in patients<\/strong> similarly to what we had demonstrated in preclinical models and activate the immune cell infiltration towards mounting immune responses against the tumor.\u201d<\/span><\/p>\n<\/blockquote>\n<p dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><strong>Pierluigi Paracchi<\/strong>, CEO of Genenta, noted:<\/p>\n<blockquote>\n<p class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><span class=\"Y2IQFc\" lang=\"it\">\u201cThe absence of limiting toxicity observed so far suggests the ability of our technology to prevent systemic toxicity in humans commonly associated with powerful anti-tumor proteins.\u201d<\/span><\/p>\n<\/blockquote>\n<p class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwilhu7E8J2EAxWKa_EDHXsxC3cQ3ewLegQICBAU\"><span class=\"Y2IQFc\" lang=\"en\">The preliminary data generated so far, including the duration of cell presence in patients, therefore, opens up interesting possibilities for the use of Temferon in a variety of solid tumors, <\/span><span class=\"Y2IQFc\" lang=\"en\">as also stated by <strong>Carlo Russo, <\/strong>CMO and Head of Development.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I\/O) company developing a cell-based platform that harnesses the power of hematopoietic stem cells to deliver durable, safe treatments for solid tumors, announced who successfully dosed the first of three patients in Cohort 8 (Temferon\u2122 at 4&#215;10^6\/kg), the final cohort of the variable-dose Phase 1 portion of the [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":18300,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[831],"tags":[],"class_list":{"0":"post-18307","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-research"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients - MakingPharmaIndustry<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I\/O) company developing a cell-based platform that harnesses the power of hematopoietic stem cells to deliver durable, safe treatments for solid tumors, announced who successfully dosed the first of three patients in Cohort 8 (Temferon\u2122 at 4&#215;10^6\/kg), the final cohort of the variable-dose Phase 1 portion of the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-09T09:37:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-09T13:05:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0\"},\"headline\":\"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients\",\"datePublished\":\"2024-02-09T09:37:43+00:00\",\"dateModified\":\"2024-02-09T13:05:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png\",\"articleSection\":[\"RESEARCH\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\",\"name\":\"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png\",\"datePublished\":\"2024-02-09T09:37:43+00:00\",\"dateModified\":\"2024-02-09T13:05:07+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0\"},\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients - MakingPharmaIndustry","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/","og_locale":"en_US","og_type":"article","og_title":"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients - MakingPharmaIndustry","og_description":"Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I\/O) company developing a cell-based platform that harnesses the power of hematopoietic stem cells to deliver durable, safe treatments for solid tumors, announced who successfully dosed the first of three patients in Cohort 8 (Temferon\u2122 at 4&#215;10^6\/kg), the final cohort of the variable-dose Phase 1 portion of the [&hellip;]","og_url":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2024-02-09T09:37:43+00:00","article_modified_time":"2024-02-09T13:05:07+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0"},"headline":"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients","datePublished":"2024-02-09T09:37:43+00:00","dateModified":"2024-02-09T13:05:07+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/"},"wordCount":286,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png","articleSection":["RESEARCH"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/","url":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/","name":"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png","datePublished":"2024-02-09T09:37:43+00:00","dateModified":"2024-02-09T13:05:07+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0"},"breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/02\/GBM.png","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/research\/genenta-dimostra-la-riprogrammazione-del-microambiente-tumorale-nei-pazienti-affetti-da-gbm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Genenta demonstrates reprogramming of the tumor microenvironment in GBM patients"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/18307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=18307"}],"version-history":[{"count":1,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/18307\/revisions"}],"predecessor-version":[{"id":18308,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/18307\/revisions\/18308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/18300"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=18307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=18307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=18307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}